A First-in-Human Study of BG-C0902
Phase 1
63
about 2 years
18+
3 sites in TX, VA
What this study is about
This trial is testing a new drug called BG-C0902 in people with advanced solid tumors. The goal is to see if the drug is safe and how it works in the body, as well as whether it can fight cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BG-C0902
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C0902, Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 1b: Overall Response Rate (ORR)
Secondary: Phase 1a and 1b: Area under the Concentration-time Curve (AUC) of BG-C0902, Total Antibody, and Payload, Phase 1a and 1b: Disease Control Rate (DCR), Phase 1a and 1b: Duration of Response (DOR), Phase 1a and 1b: Half-life (t1/2) of BG-C0902, Total Antibody, and Payload, Phase 1a and 1b: Maximum Observed Plasma Concentration (Cmax) of BG-C0902, Total Antibody, and Payload, Phase 1a and 1b: Time to Maximum Concentration (Tmax) of BG-C0902, Total Antibody, and Payload, Phase 1a: ORR, Phase 1b: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Oncology